Skip to main content
Premium Trial:

Request an Annual Quote

Accelerate Raises $20M in Rights Offering

NEW YORK (GenomeWeb News) – Accelerate Diagnostics today said it has completed a previously announced rights offering, raising $20 million.

The offering had broad participation from insiders and non-insider investors and included a standby commitment by Abeja Ventures.

Stockholders subscribed for a total of about 1.9 million shares, pursuant to their basic subscription privileges, for a participation rate of 75 percent. Shareholders also over-subscribed for a total of 1.1 million shares of which 203,062 shares were issued after exclusions based on the outcome of the basic subscription, the Tucson, Ariz.-based firm said.

A total of 413,090 shares will be issued to Abeja. In aggregate Accelerate will issue almost 2.5 million shares of its common stock, of which 1.7 million shares, or 69 percent, were acquired by company directors.

The company has said that net proceeds will go toward working capital and funding of Accelerate's business plan and product commercialization work.

On Monday, the company reported a 68 percent reduction in revenues for its second quarter.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.